University of Texas Health Science Center at Houston

UTHealth joins trial of arthritis drug’s effect on COVID-19-induced cytokine storm

Newswise — A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

The Phase III, multisite, randomized, double-blind, placebo-controlled study is evaluating the effectiveness of the drug canakinumab, an interleukin-1 (IL-1) blocker approved for the treatment of juvenile rheumatoid arthritis, for preventing cytokine release syndrome (CRS) in COVID-19 patients with pneumonia.

Often referred to as a cytokine storm, CRS is a life-threatening immune reaction caused by the body releasing too many cytokines into the blood at once. Cytokines include a broad category of proteins secreted by the body. IL-1 serves as the first-line defense for the immune system, alerting other proteins to respond if a virus or bacteria are present.

Canakinumab blocks the production of IL-1 protein, which could prevent a possible deadly overreaction of the immune system in COVID-19 patients. Research has linked a number of COVID-19 deaths to CRS due to damage caused to several major organs.

The COVID-19 pandemic has reminded researchers at UTHealth of the early days of the HIV pandemic, when confusion and fear affected many communities and few treatment options were available.

Roberto C. Arduino, MD, the study’s lead investigator and professor of infectious disease with McGovern Medical School at UTHealth, said this is a time for the HIV research community to utilize members’ expertise in the search for a treatment for the coronavirus. Arduino’s research background includes the study of new antiretroviral drugs, treatment strategies, immune activation, and inflammation in the search of a HIV cure.

“The research community truly feels compelled to do something in the search for a viable treatment for COVID-19, and I feel I owe it to my community to offer my expertise,” said Arduino, who has led HIV clinical research for 22 years.

Researchers are investigating if canakinumab combined with standard-of-care treatment can increase the chances of survival without ever requiring invasive mechanical ventilation in patients with COVID-19-induced pneumonia. Over a two-hour period, patients who are enrolled will receive either a 450 mg, 600 mg, or a 750 mg IV dose of canakinumab based on their body weight; or placebo. All participants will be monitored for up to 29 days, or until they are discharged from the hospital. A follow-up will occur at 127 days.

Novartis Pharmaceuticals and the National Institutes of Health AIDS Clinical Trials Network are sponsoring this clinical trial. For more information, visit ClinicalTrials.gov.




Filters close

Showing results

110 of 5419
Released: 15-Apr-2021 4:10 PM EDT
Penn Study Suggests Those Who Had COVID-19 May Only Need One Vaccine Dose
Perelman School of Medicine at the University of Pennsylvania

New findings from Penn suggest that people who have recovered from COVID-19 may only need a single mRNA vaccine dose. However, those who did not have COVID-19 did not have a full immune response until after a second vaccine dose, reinforcing the importance of completing the two recommended doses.

Released: 15-Apr-2021 4:00 PM EDT
June 2021 Issue of AJPH Comprises the Effects of COVID-19 on Drug Overdoses, E-cigarette Use, and Public Health Measures and Strategies
American Public Health Association (APHA)

June 2021 AJPH Issue highlights COVID-19 concerns in relation to fatal drug overdoses, drops in youth e-cigarette use, importance of public health measures, and strategies to protect correctional staff.

Newswise: 262150_web.jpg
Released: 15-Apr-2021 3:20 PM EDT
COVID-19 reduces access to opioid dependency treatment for new patients
Princeton University

COVID-19 has been associated with increases in opioid overdose deaths, which may be in part because the pandemic limited access to buprenorphine, a treatment used for opioid dependency, according to a new study led by Princeton University researchers.

Newswise: UGA to Establish National NIH-funded Center to Fight Flu
Released: 15-Apr-2021 2:45 PM EDT
UGA to Establish National NIH-funded Center to Fight Flu
University of Georgia

The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research (CIDER). The contract will provide $1 million in first-year funding and is expected to be supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, for seven years and up to approximately $92 million.

Released: 15-Apr-2021 2:15 PM EDT
Meatpacking plants increased COVID-19 cases in US counties
University of California, Davis

An estimated 334,000 COVID-19 cases are attributable to meatpacking plants, resulting in $11.2 billion in economic damage, according to a new study led by a researcher at the University of California, Davis.

Newswise: 262052_web.jpg
Released: 15-Apr-2021 1:55 PM EDT
How to build a city that prioritizes public health
Colorado State University

Most people by now have memorized the public health guidelines meant to help minimize transmission of COVID-19: wash your hands, wear a mask, keep six feet apart from others. That part is easy.

Released: 15-Apr-2021 1:45 PM EDT
Wake Forest School of Medicine Begins Study to Test New Mask for Healthcare Workers
Wake Forest Baptist Health

Open Standard Industries, Inc. (OSI), manufacturer of the OSR-M1 non-valved reusable elastomeric face mask, is pleased to formally announce the launch of its first Institutional Review Board (IRB)-approved user feasibility study. The trial is being led by the departments of Biomedical Engineering and Infectious Diseases at Wake Forest School of Medicine, part of Wake Forest Baptist Health. Recruitment in the study is underway, and enrollment is expected to be completed by May 28, 2021.

Newswise: Major clinical trial to test Pfizer-BioNTech COVID-19 vaccine opens for enrollment at UTHealth in Houston
Released: 15-Apr-2021 1:45 PM EDT
Major clinical trial to test Pfizer-BioNTech COVID-19 vaccine opens for enrollment at UTHealth in Houston
University of Texas Health Science Center at Houston

A large national clinical trial to evaluate the Pfizer-BioNTech COVID-19 vaccine for safety and efficacy in pregnant women is now open for enrollment at The University of Texas Health Science Center at Houston (UTHealth).

Released: 15-Apr-2021 1:15 PM EDT
For veterans, a hidden side effect of COVID: Feelings of personal growth
Yale University

The U.S. military veteran population is known to have abnormally high rates of suicide, so health officials have been concerned that the COVID-19 pandemic might elevate risk of psychiatric disorders, particularly among those suffering from post-traumatic stress and related disorders.

Newswise: 262026_web.jpg
Released: 15-Apr-2021 12:55 PM EDT
Significant spread of all coronavirus variants tracked in Houston area
Elsevier

In late 2020, several concerning SARS-CoV-2 variants emerged globally. They are believed to be more easily transmissible, and there is concern that some may reduce the effectiveness of antibody treatments and vaccines.


Showing results

110 of 5419

close
1.38952